Using CRISPR/Cas9, we generated a spectrum of mutation combinations (PT: PTEN-/-; TP53-/-, PTCC: PTEN-/-; TP53-/-; CDKN2A-/-; CDKN2B-/-, PTN: PTEN-/-; TP53-/-; NF1-/-), which are among the most frequently mutated tumor suppressors in GBM patients5, in two iPSCs derived from healthy donor, one cell line expressing GFP. This evidence concerns the gene PTEN and neoplasm.